Valuation: Atossa Therapeutics, Inc.

Market Cap 20.41M 17.9M 16.58M 15.25M 28.85M 1.95B 29.42M 198M 77.5M 959M 76.64M 74.96M 3.31B P/E 2026 *
-0.55x
P/E 2027 * -0.68x
Enterprise Value 20.41M 17.9M 16.58M 15.25M 28.85M 1.95B 29.42M 198M 77.5M 959M 76.64M 74.96M 3.31B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.29%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Atossa Therapeutics, Inc.

1 day+1.27%
1 week+3.51%
Current month+22.28%
1 month+0.43%
3 months-55.56%
6 months-75.25%
Current year-73.33%
1 week 2.19
Extreme 2.19
2.6
1 month 1.7
Extreme 1.7
2.6
Current year 1.7
Extreme 1.7
10.95
1 year 1.7
Extreme 1.7
19.35
3 years 1.7
Extreme 1.7
34.65
5 years 1.7
Extreme 1.7
107.25
10 years 1.7
Extreme 1.7
806.76
Manager TitleAgeSince
Chief Executive Officer 75 01/04/2009
Director of Finance/CFO 50 14/10/2025
Chief Tech/Sci/R&D Officer - 01/10/2025
Director TitleAgeSince
Chairman 75 01/04/2009
Director/Board Member 64 01/04/2009
Director/Board Member 79 01/07/2011
Date Insider Type Main position Quantity % Market Cap.
05-12Free

Director

10,000 0.1161%
05-12Free

Director

10,000 0.1161%
05-12Free

Founder

10,000 0.1161%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+3.51%-83.20%-87.00% 20.41M
+0.44%+1.41%+4.25%+10.81% 50.73B
-1.88%-4.21%+374.32%+586.00% 39.73B
-0.20%+0.88%+29.76%-5.40% 34.69B
+1.79%-1.75%+20.59%+53.43% 33.21B
-0.06%-4.63%+2.94%+31.65% 26.76B
-1.96%-1.33% - - 16.8B
-1.56%-6.19%+65.48%+120.50% 15.37B
+0.78%+1.16%+15.53%+17.32% 13.78B
-0.71%-3.16%+10.71%-33.52% 12.85B
Average -0.34%-1.30%+48.93%+77.09% 24.39B
Weighted average by Cap. -0.40%-1.31%+80.30%+122.93%

Financials

2026 *2027 *
Net sales - -
Net income -37.39M -32.8M -30.38M -27.95M -52.87M -3.58B -53.89M -362M -142M -1.76B -140M -137M -6.07B -39.31M -34.48M -31.94M -29.38M -55.58M -3.76B -56.66M -381M -149M -1.85B -148M -144M -6.38B
Net Debt - -
Logo Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of unmet medical need in oncology with a focus on women’s breast cancer and other breast conditions. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. It is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. It has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations).
Employees
16
Date Price Change Volume
14/07/26 US$2.370 0.00% 161,672
10/07/26 US$2.370 +0.42% 65,745
09/07/26 US$2.360 -3.67% 144,165
08/07/26 US$2.450 -1.61% 127,999
07/07/26 US$2.490 +9.21% 426,355
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.370USD
Average target price
22.00USD
Spread / Average Target
+828.27%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ATOS Stock